Showing results (691-700 of 1,351) with videos related to

Sort By:
Pageof 136
Clinical Pharmacology in Drug Development|May 4, 2016
Population pharmacokinetic/pharmacodynamic assessment of pharmacological effect of a selective estrogen receptor β agonist on total testosterone in healthy menLeijun Hu, Yan Jin, Ying Grace Li, et al.
Clinical Pharmacology in Drug Development|May 4, 2016
Single-dose pharmacokinetics of bupropion hydrobromide and metabolites in healthy adolescent and adult subjectsD Alexander Oh, Christopher S Crean
Clinical Pharmacology in Drug Development|May 4, 2016
Evaluation of the effect of food and age on the pharmacokinetics of oral netupitant and palonosetron in healthy subjects: A randomized, open-label, crossover phase 1 studySelma Calcagnile, Corinna Lanzarotti, Michaela Gutacker, et al.
Clinical Pharmacology in Drug Development|May 4, 2016
A single- and multiple-dose study to investigate the pharmacokinetics of epelsiban and its metabolite, GSK2395448, in healthy female volunteersKelly M Mahar, Brendt Stier, Michael Fries, et al.
Clinical Pharmacology in Drug Development|May 4, 2016
Safety, bioavailability, and pharmacokinetics of VGX-1027-A novel oral anti-inflammatory drug in healthy human subjectsJessica C Lee, Stanley Menacherry, Malissa C Diehl, et al.
Clinical Pharmacology in Drug Development|May 4, 2016
Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence TechnologyMona Darwish, Ronghua Yang, William Tracewell, et al.
Clinical Pharmacology in Drug Development|May 4, 2016
Opicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched white subjectsAmílcar Falcão, José Francisco Rocha, Ana Santos, et al.
Clinical Pharmacology in Drug Development|May 4, 2016
An Exposure-Response Modeling Approach to Examine the Relationship Between Potency of CYP3A Inducer and Plasma 4β-Hydroxycholesterol in Healthy SubjectsXuemin Jiang, Catherine Dutreix, Venkateswar Jarugula, et al.
Clinical Pharmacology in Drug Development|February 28, 2021
Differential Effect of a Continental Breakfast on Tacrolimus Formulations With Different Release CharacteristicsAndrea Huppertz, Johanna Bollmann, Rouven Behnisch, et al.
Clinical Pharmacology in Drug Development|August 31, 2019
Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT StudyMarie T Borin, Chris N Barnes, Borje Darpo, et al.
Pageof 136